tbuckley/cabot-search huggingface dataset:
Breast-Cancer Risk in Families with Mutations in <i>PALB2</i>
Authors: Antonis C. Antoniou, Silvia Casadei, Tuomas Heikkinen, Daniel Barrowdale, Katri Pylkäs, Jonathan Roberts, Andrew Lee, Deepak Subramanian, Kim De Leeneer, Florentia Fostira, Eva Tomiak, Susan L. Neuhausen, Zhi L. Teo, Sofia Khan, Kristiina Aittomäki, Jukka S. Moilanen, Clare Turnbull, Sheila Seal, Arto Mannermaa, Anne Kallioniemi, Geoffrey J. Lindeman, Saundra S. Buys, Irene L. Andrulis, Paolo Radice, Carlo Tondini, Siranoush Manoukian, Amanda E. Toland, Penelope Miron, Jeffrey N. Weitzel, Susan M. Domchek, Bruce Poppe, Kathleen B.M. Claes, Drakoulis Yannoukakos, Patrick Concannon, Jonine L. Bernstein, Paul A. James, Douglas F. Easton, David E. Goldgar, John L. Hopper, Nazneen Rahman, Paolo Peterlongo, Heli Nevanlinna, Mary-Claire King, Fergus J. Couch, Melissa C. Southey, Robert Winqvist, William D. Foulkes, Marc Tischkowitz
Journal: New England Journal of Medicine (2014)

Germline loss-of-function mutations in PALB2 are known to confer a predisposition to breast cancer. However, the lifetime risk of breast cancer that is conferred by such mutations remains unknown.
Systemic Lupus Erythematosus
Authors: John A. Mills
Journal: New England Journal of Medicine (1994)

Systemic Lupus Erythematosus (SLE) is defined by its clinical features and by the almost invariable presence in the blood of antibodies directed against one or more components of cell nuclei. Certain manifestations seem to be associated with the presence of different antinuclear antibodies and genetic markers, which suggests that SLE may be a family of diseases. However, clinical presentations frequently overlap, and there is currently no conclusive evidence that SLE is more than a single disorder with a broad range of manifestations, the expression of which may be influenced by the patient's genetic background. Occasionally patients have features of both . . .
A Single Bacterial Immune Evasion Strategy Dismantles Both MyD88 and TRIF Signaling Pathways Downstream of TLR4
Authors: Charles V. Rosadini, Ivan Zanoni, Charlotte Odendall, Erin R. Green, Michelle K. Paczosa, Naomi H. Philip, Igor E. Brodsky, Joan Mecsas, Jonathan C. Kagan
Journal: Cell Host & Microbe (2015)
Enoxaparin reduces hepatic vascular resistance and portal pressure in cirrhotic rats
Authors: Federica Cerini, Marina Vilaseca, Erica Lafoz, Oihane García-Irigoyen, Héctor García-Calderó, Dinesh M. Tripathi, Matias Avila, Juan Carlos Reverter, Jaime Bosch, Jordi Gracia-Sancho, Juan Carlos García-Pagán
Journal: Journal of Hepatology (2015)
Infant Growth and Risk of Childhood-Onset Type 1 Diabetes in Children From 2 Scandinavian Birth Cohorts
Authors: Maria C. Magnus, Sjurdur F. Olsen, Charlotta Granström, Geir Joner, Torild Skrivarhaug, Jannet Svensson, Jesper Johannesen, Pål Njølstad, Per Magnus, Ketil Størdal, Lars C. Stene
Journal: JAMA Pediatrics (2015)

Type 1 diabetes mellitus is one of the most common chronic diseases with onset in childhood, but environmental risk factors have not been convincingly established.To test whether increased growth during the first year of life is associated with higher risk of childhood-onset type 1 diabetes.This is a cohort study using information from 2 population-based cohort studies in Norway and Denmark, the Norwegian Mother and Child Cohort Study (MoBa) and the Danish National Birth Cohort (DNBC), of children born between February 1998 and July 2009. The current study was conducted between November 2014 and June 2015.Change in weight and length from birth to age 12 months.Unadjusted and adjusted hazard ratios (HRs) of type 1 diabetes, classified based on nationwide childhood diabetes registers, obtained using Cox proportional hazards regression.A total of 99,832 children were included in the study, with 59,221 in MoBa (51.2% boys and 48.8% girls; mean age at end of follow-up, 8.6 years [range, 4.6-14.2 years]) and 40,611 in DNBC (50.6% boys and 49.4% girls; mean age at end of follow-up, 13.0 years [range, 10.4-15.7 years]). The incidence rate of type 1 diabetes from age 12 months to the end of follow-up was 25 cases per 100,000 person-years in DNBC and 31 cases per 100,000 person-years in MoBa. The change in weight from birth to 12 months was positively associated with type 1 diabetes (pooled unadjusted HR = 1.24 per 1-SD increase; 95% CI, 1.11-1.39; pooled adjusted HR = 1.24 per 1-SD increase; 95% CI, 1.09-1.41). There was no significant association between length increase from birth to 12 months and type 1 diabetes (pooled unadjusted HR = 1.06 per 1-SD increase; 95% CI, 0.93-1.22; pooled adjusted HR = 1.06 per 1-SD increase; 95% CI, 0.86-1.32). The associations were similar in both sexes.This is the first prospective population-based study, to our knowledge, providing evidence that weight increase during the first year of life is positively associated with type 1 diabetes. This supports the early environmental origins of type 1 diabetes.
Erratum. Vitamin D Supplementation and the Effects on Glucose Metabolism During Pregnancy: A Randomized Controlled Trial. Diabetes Care 2014;37:1837–1844
Authors: Constance Yap, N. Wah Cheung, Jenny E. Gunton, Neil Athayde, Craig F. Munns, Anna Duke, Mark McLean
Journal: Diabetes Care (2015)

In the print version of the article cited above, there are several minor errors in Tables 1 and 2. These errors do not affect the results or …
High-Resolution Magnetic Resonance Imaging Can Reliably Detect Orbital Tumor Recurrence after Enucleation in Children with Retinoblastoma
Authors: Selma Sirin, Marcus C. de Jong, Pim de Graaf, Hervé J. Brisse, Paolo Galluzzi, Philippe Maeder, Norbert Bornfeld, Eva Biewald, Klaus A. Metz, Petra Temming, Jonas A. Castelijns, Sophia L. Goericke, Jonas A. Castelijns, Pim de Graaf, Marcus C. de Jong, Hervé J. Brisse, Paolo Galluzzi, Sophia L. Göricke, Selma Sirin, Philippe Maeder
Journal: Ophthalmology (2015)
Ten-eleven translocation 1 (TET1) methylation is associated with childhood asthma and traffic-related air pollution
Authors: Hari K. Somineni, Xue Zhang, Jocelyn M. Biagini Myers, Melinda Butsch Kovacic, Ashley Ulm, Noelle Jurcak, Patrick H. Ryan, Gurjit K. Khurana Hershey, Hong Ji
Journal: Journal of Allergy and Clinical Immunology (2015)
P-262 The impact of variations in KRAS codon 12 and 13 point mutation on the efficacy of cytotoxic chemotherapy for metastatic colorectal cancer (CRC)
Authors: I. Nakayama, E. Shinozaki, T. Wakatsuki, M. Ogura, M. Ozaka, M. Suenaga, N. Mizunuma
Journal: Annals of Oncology (2015)
Histopathologic assessment of depth of follicular invasion of squamous cell carcinoma (SCC) in situ (SCCis): Implications for treatment approach
Authors: Sean R. Christensen, Jennifer M. McNiff, Alicia J. Cool, Sumaira Z. Aasi, Allison M. Hanlon, David J. Leffell
Journal: Journal of the American Academy of Dermatology (2015)
Quality and Safety in Health Care, Part VII
Authors: Jay A. Harolds
Journal: Clinical Nuclear Medicine (2015)

The Institute of Medicine report entitled The Health Care Imperative: Lowering Costs and Improving Outcomes discussed numerous ways to decrease costs in the health care system without decreasing quality. The use of evidence-based medicine, eliminating wasteful spending such as needlessly high administrative costs, having more preventive services, having a better reimbursement system that emphasized quality, developing a less fragmented and more efficient medical delivery system, having more transparency for patients on the outcomes of different providers, having greater health care literacy for patients, and eliminating fraud were some of the recommendations. The total savings from eliminating unnecessary health care costs was estimated to be over 3 quarters of a trillion dollars each year.
Moving Beyond “Food Deserts”: Reorienting United States Policies to Reduce Disparities in Diet Quality
Authors: Jason P. Block, S. V. Subramanian
Journal: PLoS Medicine (2015)

Points• Most Americans fail to meet recommendations for diet quality, with disparities evident by race/ethnicity, socioeconomic status, and use of nutrition assistance programs.• The evidence supporting the elimination of food deserts as a strategy to reduce disparities in diet quality is weak.• More use of evidence-based policies to improve diet quality and reduce disparities in the United States is needed, specifically for school-and child care-based interventions, useful population educational strategies, changes to nutrition assistance programs, and taxation of unhealthy foods such as sugar-sweetened beverages.
New Rates of Interventions to Manage Complications of Modern Prostate Cancer Treatment in Older Men
Authors: Christopher J.D. Wallis, Alyson Mahar, Patrick Cheung, Sender Herschorn, Laurence H. Klotz, Ashraf Al-Matar, Girish S. Kulkarni, Yuna Lee, Ronald T. Kodama, Steven A. Narod, Robert K. Nam
Journal: European Urology (2015)
Anti-mesothelin vaccine CRS-207 with or without low-dose cyclophosphamide plus chemotherapy as front-line treatment for malignant pleural mesothelioma (MPM)
Authors: Raffit Hassan, Evan Alley, Hedy Kindler, Scott Antonia, Thierry Jahan, Anish Thomas, Somayeh Honarmand, Aimee L Murphy, John J Grous, Dirk G Brockstedt
Journal: Journal for ImmunoTherapy of Cancer (2015)

Meeting abstracts CRS-207 is live-attenuated, double-deleted Listeria monocytogenes (LADD) engineered to express the tumor-associated antigen mesothelin which is highly expressed in malignant pleural mesothelioma (MPM). CRS-207 stimulates potent innate and adaptive immunity and in combination with
Directing vaccine immune responses to mucosa by nanosized particulate carriers encapsulating NOD ligands
Authors: Vincent Pavot, Nuria Climent, Nicolas Rochereau, Felipe Garcia, Christian Genin, Gérard Tiraby, Fabienne Vernejoul, Eric Perouzel, Thierry Lioux, Bernard Verrier, Stéphane Paul
Journal: Biomaterials (2015)
Primary care is still treated with “contempt,” says outgoing leader
Authors: Adrian O’Dowd
Journal: BMJ (2015)

Primary care is still treated unfairly and with longstanding “contempt” in the United Kingdom, and there is too much focus on hospitals’ needs and finances, says a leading primary care representative.

Michael Dixon, the outgoing chair of the primary care representative body the NHS Alliance, gave a critical speech to leaders from across the NHS on 8 December at a retirement event …
How I was nearly duped into “authoring” a fake paper
Authors: Per Aspenberg
Journal: BMJ (2015)

Academics need to beware of the dangers of flattery, says Per Aspenberg 

In February 2015, I was invited to join an academic working group to analyse procedures for increasing bone mass, structure, and strength through “intraosseous interventions.” The group, which included some of the world’s most prominent osteoporosis researchers, was meeting at a luxury hotel in Switzerland as part of the preparations for the world congress on osteoporosis. I was asked to give a presentation on “currently available orthopaedic procedures for bone enhancement.”

The subject puzzled me, because there are no such procedures. But I was flattered by the invitation so rather than decline I spent several days preparing a presentation in which I concluded that prophylactic surgery in osteoporosis was not a good idea.

One week before the meeting I received an email from a professional medical writer, attaching a synopsis for the meeting in which I …
Sensitization to cat and dog allergen molecules in childhood and prediction of symptoms of cat and dog allergy in adolescence: A BAMSE/MeDALL study
Authors: Anna Asarnoj, Carl Hamsten, Konrad Wadén, Christian Lupinek, Niklas Andersson, Inger Kull, Mirela Curin, Josep Anto, Jean Bousquet, Rudolf Valenta, Magnus Wickman, Marianne van Hage
Journal: Journal of Allergy and Clinical Immunology (2015)
THE ALLOGENEIC EFFECT IN INBRED MICE
Authors: David H. Katz, David P. Osborne
Journal: The Journal of Experimental Medicine (1972)

Experimental conditions have been established for the elicitation of an allogeneic effect on the adoptive transfer secondary anti-2,4-dinitrophenyl (DNP) antibody response in mice. Thus, spleen cells from DNP-keyhole limpet hemocyanin (KLH)-primed mice manifest good secondary anti-DNP responses to a challenge with DNP-KLH, but not with DNP-bovine gamma globulin (BGG), after adoptive transfer to irradiated syngeneic recipients. However, a good adoptive transfer secondary anti-DNP response of such cells can be elicited with DNP-BGG when a second transfer of allogeneic lymphoid cells, in appropriate numbers, is carried out 24 hr before secondary challenge. The advantage to this system is that the DNP-primed cell population as well as the population of allogeneic lymphoid cells are accessible to experimental manipulation such that the T lymphocytes of one or the other can be removed. Utilizing this model, we have established that the allogeneic effect on antibody production can operate on a population of primed B lymphocytes which have been depleted of their isologous T lymphocytes by in vitro incubation with anti-theta serum plus complement. The potential cellular interactions involved in the mechanism of this phenomenon are considered and discussed in detail.
Extrapulmonary tuberculosis (TB): 40 years observations in Poland
Authors: Maria Korzeniewska-Kosela
Journal: European Respiratory Journal (2012)

Aim of the study: To describe changes in extrapulmonary TB epidemiology in Poland since 1970 (beginning of notification of different forms of extrapulmonary TB)

Methods: Retrospective analysis of data from National TB Register. Data presented in ten years intervals.

Results: Since 1970 the systematic decline of number of all TB cases (from 41536 to7509 in 2010) with the shift to older age groups and decline of extrapulmonary TB cases (from 4848 to 716 in 2010) has been recorded in Poland without significant differences of fraction of extrapulmonary TB among all TB cases (11.6% in 1970; 11.2% in 1980 to 9.0% in 1990, and 9.8% in 2000, 9.5% in 2010). Some differences in profile of extrapulmonary TB was noticed. The decrease in pleural tuberculosis occurred (5.8% of all TB and 50% of extrapulmonary TB in 1970; 5.8% and 49.6% in 1980; 4.8% and 52% in 1990; 5.2% and 53.8% in 2000; 2.6% and 27.8% in 2010) and in the bone and joint tuberculosis (2.0% of all TB and 17.3% of extrapulmonary TB in 1970; 1.4% and 12, 9% in 1980; 0.9% and 10.2% in 1990; 0.9% and 9.1% in 2000; 0.9% and 9.2% in 2010) also in central nervous system TB (0.3% of all TB and 2.8% of extrapulmonary TB in 1970; 0.2% and 1.9% in 1980, 0.1% and 1.7% in 1990, 0.1% and 1.4% in 2000; 0.1% and 1.3% in 2010).

Conclusions. The demographic characteristics of TB patients changed in Poland in last 40 years with the shift to older age groups however the proportion of TB at extrapulmonary sites remained stable. It is interesting although unexplained finding.
Call to Action for General Surgery–Trained Specialists
Authors: Gerard M. Doherty
Journal: JAMA Surgery (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update
Authors: L Gossec, J S Smolen, S Ramiro, M de Wit, M Cutolo, M Dougados, P Emery, R Landewé, S Oliver, D Aletaha, N Betteridge, J Braun, G Burmester, J D Cañete, N Damjanov, O FitzGerald, E Haglund, P Helliwell, T K Kvien, R Lories, T Luger, M Maccarone, H Marzo-Ortega, D McGonagle, I B McInnes, I Olivieri, K Pavelka, G Schett, J Sieper, F van den Bosch, D J Veale, J Wollenhaupt, A Zink, D van der Heijde
Journal: Annals of the Rheumatic Diseases (2015)

Background Since the publication of the European League Against Rheumatism recommendations for the pharmacological treatment of psoriatic arthritis (PsA) in 2012, new evidence and new therapeutic agents have emerged. The objective was to update these recommendations. Methods A systematic literature review was performed regarding pharmacological treatment in PsA. Subsequently, recommendations were formulated based on the evidence and the expert opinion of the 34 Task Force members. Levels of evidence and strengths of recommendations were allocated. Results The updated recommendations comprise 5 overarching principles and 10 recommendations, covering pharmacological therapies for PsA from non-steroidal anti-inflammatory drugs (NSAIDs), to conventional synthetic (csDMARD) and biological (bDMARD) disease-modifying antirheumatic drugs, whatever their mode of action, taking articular and extra-articular manifestations of PsA into account, but focusing on musculoskeletal involvement. The overarching principles address the need for shared decision-making and treatment objectives. The recommendations address csDMARDs as an initial therapy after failure of NSAIDs and local therapy for active disease, followed, if necessary, by a bDMARD or a targeted synthetic DMARD (tsDMARD). The first bDMARD would usually be a tumour necrosis factor (TNF) inhibitor. bDMARDs targeting interleukin (IL)12/23 (ustekinumab) or IL-17 pathways (secukinumab) may be used in patients for whom TNF inhibitors are inappropriate and a tsDMARD such as a phosphodiesterase 4-inhibitor (apremilast) if bDMARDs are inappropriate. If the first bDMARD strategy fails, any other bDMARD or tsDMARD may be used. Conclusions These recommendations provide stakeholders with an updated consensus on the pharmacological treatment of PsA and strategies to reach optimal outcomes in PsA, based on a combination of evidence and expert opinion.
A Randomized, Double-Blind, Multicenter Comparison Study of Triple Antiplatelet Therapy With Dual Antiplatelet Therapy to Reduce Restenosis After Drug-Eluting Stent Implantation in Long Coronary Lesions
Authors: Seung-Whan Lee, Seong-Wook Park, Young-Hak Kim, Sung-Cheol Yun, Duk-Woo Park, Cheol Whan Lee, Soo-Jin Kang, Seung-Jung Park, Jae-Hwan Lee, Si Wan Choi, In-Whan Seong, Nae-Hee Lee, Yoon Haeng Cho, Won-Yong Shin, Seung-Jin Lee, Se-Whan Lee, Min-Su Hyon, Duk-Won Bang, Young-Jin Choi, Hyun-Sook Kim, Bong-Ki Lee, Keun Lee, Hoon-Ki Park, Chang-Bum Park, Sang-Gon Lee, Min-Kyu Kim, Kyoung-Ha Park, Woo-Jung Park
Journal: Journal of the American College of Cardiology (2011)
GW26-e0456 Exosomes Derived From Dendritic Cells Activate CD4+ T Lymphocytes After Myocardial Infarction
Authors: Haibo Liu, Wangjun Yu, Chunming Wang, Xiaofang Guo, Kang Yao, Jie Yuan, Yunzeng Zou, Junbo Ge
Journal: Journal of the American College of Cardiology (2015)
Abstract #3604: A phase I single-rising dose study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of an oral akt inhibitor in healthy male volunteers
Authors: Michele Trucksis, Evan Friedman, Adekemi Taylor, Liliana Delgado, Tom Reynders, Marina DeSmet, Yingwen Dong, Irong Fu, Igance DeMeyer, Jeffrey Chodakewitz, Marian Iwamoto, John Wagner
Journal: Cancer Research (2009)

Background:  MK-2206 is an orally active, allosteric Akt inhibitor which in preclinical models showed antitumor effects.  Methods:  Twenty-four healthy, male subjects participated in a Phase I randomized, double-blind, placebo-controlled, sequential-panel, multiple-period, rising single oral dose study of MK-2206. Eight (8) subjects were assigned to each of 3 panels (Panels A, B, and C) where in each treatment period in a panel the same 6 subjects received MK-2206 and 2 subjects received placebo after an overnight fast. The volunteers were administered single doses from 0.25 to 100 mg and blood samples were collected predose and at prespecified postdose timepoints for pharmacokinetic and pharmacodynamic (whole blood inhibition of phospho Akt) assays.  Results:  Single doses of MK-2206, up to 100 mg, were found to be generally well tolerated. No serious clinical or laboratory adverse experience was reported. The most commonly reported adverse experiences were headache, common cold, and diarrhea. One subject was discontinued from the study due to the clinical adverse experience of blurry vision which resolved. There were no clinically meaningful changes in laboratory safety tests and ECG evaluations. Preliminary pharmacokinetic results found that orally administered MK-2206 was readily absorbed with a median T max  of 6 to 8 hours. The median half-life was 55 to 78 hours. AUC 0-\#8734;  and C max  displayed dose proportional behavior from 2-mg to 100-mg. Preliminary pharmacodynamic results found that single doses of 40-, 80- and 100-mg MK-2206 inhibited Akt in whole blood to a greater extent than placebo. Maximum Akt inhibition occurred at 6 hours postdose for both the 80- and 100-mg doses with mean plasma concentrations of >65 nM. There was evidence of Akt inhibition from 2 through 24 hours.  Conclusion:  MK-2206 is an antitumor agent which was generally well tolerated following single dose administration to healthy subjects. MK-2206 displays dose proportional pharmacokinetics with clear evidence of Akt inhibition.   Citation Information:  In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 3604.
Association of pooled cohort risk scores with vascular inflammation and coronary artery calcification in Korean adults
Authors: Hye Jin Yoo, Hwan Seok Yong, Soon Young Hwang, Jae Seon Eo, Ho Cheol Hong, Ji A. Seo, Sin Gon Kim, Nan Hee Kim, Dong Seop Choi, Sei Hyun Baik, Kyung Mook Choi
Journal: Metabolism (2015)